



October 16, 2025

Company Name:	GNI Group Ltd.
Representative:	Director, Representative Executive Officer, President and CEO Ying Luo, PhD (Security Code: 2160, TSE Growth)
Contact Person:	Director, Executive Officer, Vice President COO and CFO Ryosuke Matsui (TEL. 03-6214-3600)

Notice of Completion of Subject Enrollment in the Phase 3 Clinical Trial of Pirfenidone Capsule for the Treatment of Pneumoconiosis Conducted by Key Subsidiary Gyre Therapeutics

(Note) This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the Japanese original shall prevail.

GNI Group Ltd. ("the Company") announces that its key subsidiary, Gyre Therapeutics, Inc. ("GYRE"), has completed subject enrollment in the Phase 3 clinical trial of Class 1.1 new drug "Pirfenidone Capsule" (product name: Etuary®), for a new indication in the treatment of pneumoconiosis.

A total of 272 patients have been enrolled in this multicenter, randomized, double-blind, placebo-controlled trial being conducted at 18 clinical research centers across China. The trial is designed to evaluate the efficacy and safety of 52 weeks of Pirfenidone capsule treatment in patients with pneumoconiosis, a chronic occupational lung disease characterized by progressive pulmonary fibrosis.

GYRE's press release is available at the following link:

[Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis](#)

The impact of this matter on the Company's consolidated financial results for the current fiscal year is expected to be immaterial.